Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US

PURPOSE: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US. PAT...

Descripción completa

Detalles Bibliográficos
Autores principales: McGrath, Leah J, Overman, Robert A, Reams, Diane, Cetin, Karynsa, Liede, Alexander, Narod, Steven A, Brookhart, M Alan, Hernandez, Rohini K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162990/
https://www.ncbi.nlm.nih.gov/pubmed/30288124
http://dx.doi.org/10.2147/CLEP.S175063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162990/
https://www.ncbi.nlm.nih.gov/pubmed/30288124
http://dx.doi.org/10.2147/CLEP.S175063

Ejemplares similares